WallStSmart

POMDOCTOR LIMITED American Depositary Shares (POM)vsRidgetech, Inc. (RDGT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

POMDOCTOR LIMITED American Depositary Shares generates 203% more annual revenue ($399.92M vs $132.16M). RDGT leads profitability with a -0.9% profit margin vs -53.2%. RDGT earns a higher WallStSmart Score of 39/100 (F).

POM

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -33.39

RDGT

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 4.0Value: 6.7Quality: 8.0
Piotroski: 4/9Altman Z: 2.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for POM.

RDGTUndervalued (+82.8%)

Margin of Safety

+82.8%

Fair Value

$10.36

Current Price

$0.83

$9.53 discount

UndervaluedFair: $10.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

POM2 strengths · Avg: 9.0/10
Debt/EquityHealth
-1.0010/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
17.2%8/10

17.2% revenue growth

RDGT4 strengths · Avg: 9.5/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
30.2%10/10

Every $100 of equity generates 30 in profit

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
21.4%8/10

Revenue surging 21.4% year-over-year

Areas to Watch

POM4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.19M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RDGT4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.39M3/10

Smaller company, higher risk/reward

Free Cash FlowQuality
$-6.74M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-0.9%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : POM

The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.

Bull Case : RDGT

The strongest argument for RDGT centers on Price/Book, Return on Equity, Debt/Equity. Revenue growth of 21.4% demonstrates continued momentum.

Bear Case : POM

The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.

Bear Case : RDGT

The primary concerns for RDGT are EPS Growth, Market Cap, Free Cash Flow.

Key Dynamics to Monitor

RDGT is growing revenue faster at 21.4% — sustainability is the question.

RDGT generates stronger free cash flow (-7M), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RDGT scores higher overall (39/100 vs 28/100) and 21.4% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

POMDOCTOR LIMITED American Depositary Shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.

Visit Website →

Ridgetech, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

China Jo-Jo Drugstores, Inc. is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company is headquartered in Hangzhou, the People's Republic of China.

Visit Website →

Want to dig deeper into these stocks?